Peptide immunization in humans: A combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL)

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 18-25

  Brander, C ^a,d   Corradin, G ^b   Hasler, T ^c   Pichler, W J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Berna Biotech AG   (Switzerland)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CTL; HIV; peptide immunization; T helper epitope; vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AMINO ACID; ANTIBODY; ANTIGEN; C REACTIVE PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; PEPTIDE; TETANUS TOXIN; TUMOR NECROSIS FACTOR ALPHA; VACCINE; WATER;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; MALE; MEMORY CELL; MONONUCLEAR CELL; MYALGIA; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030015945     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-725.x     Document Type: Article

References (41)

1. Borysiewiez L, Graham S, Hickling JK, Mason P, Sissons JGP. Human cytomeglovirus specific cytoloxic T cells: their precursor frequency and stage specificity. Eur J Immunol 1988; 18:269-75.
2. Murray N, McMichael AJ. Antigen presentation in virus infection. Curr Opin Immunol 1992; 4:401-7.
3. Walker BD, Chakrabarti S, Moss B et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328:345-8.
4. Walker BD, Flexner C, Birch-Limberger K et al. Long-term culture and fine specificity of human T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989; 86:9514-8.
5. Buseyne F, Blanche S, Schmitt D, Griscelli C, Rivière Y. Detection of IIIV-specific cell mediated cytotoxicity in the peripheral blood from infected children. J Immunol 1993; 150:3569-81.
6. Autran B, Plata F, Debre P. MHC restricted cytotoxicity against HIV. J Acq Immune Defic Syndromes 1991; 2:398-403.
7. Nixon DF, McMichael AJ. Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991; 5:1049-59.
8. Sabin A. HIV vaccination dilemma. Nature 1993; 362:212.
9. Letvin NL. Vaccines against human immunodeficiency virus-progress and prospects. N Engl J Med 1993; 329:1400-5.
10. Kast WM, Roux L, Curren J et al. Protection against lethal Sendai virus infection by in-vivo priming of virus-specific, cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991; 88:2283-7.
11. Rammensee HG, Falk K, Rötzschke O. MHC molecules as peptide receptors. Curr Opin Immunol 1993; 5:35-44.
12. Shafferman A, Jahrling PB, Benveniste RE et al. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci USA 1991; 88:7126-30.
13. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci USA 1991; 88:991-3.
14. Arnon R, Horwitz RJ. Synthetic peptides as vaccines. Curr Opin Immunol 1992; 4:449-53.
15. Berzofsky JA. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Biotech Therap 1991; 2:123-35.
16. Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D. T-helper epitopes enhance the cytotoxic response of mice immunized with MHC class I restricted malaria peptides. J Immunol Methods 1992; 155:95-99.
17. Valmori D, Romero JF, Maryanski J, Romero P, Corradin G. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Ear J Immunol 1994; 24:1458-62.
18. Vitiello A, Ishioka G, Grey H et al. Development of a lipopeptidebased therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95:341-9.
19. Sauzet JP, Deprez B, Martinon F et al. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 1995; 13:1339-45.
20. Deres K, Schild H, Wiesmüller KH. Jung G, Rammensee HG. In-vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989: 342:561-6.
21. Demotz S, Lanzavecchia A, Eisel U, Niemann H, Widmann C, Corradin G. Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 1989; 142:394-402.
22. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19:2237-42.
23. Valmori D, Pessi A, Bianchi E, Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 1992; 149:717-21.
24. Brander C, Pichler WJ, Corradin G. Identification of HIV-protein derived CTL epitopes for their potential use as synthetic vaccine. Clin Exp Immunol 1995; 101:107-13.
25. Nixon DF, Broliden K, Ogg G, Broliden PA. Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992; 76:515-34.
26. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290-6.
27. Townsend A. Öhlén C, Bastin J, Ljunggren HG, Foster L, Kärre K. Association of class 1 major histocompatibility heavy and light chains induced by, viral peptides. Nature 1989; 340:443-8.
28. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75.
29. Dadaglio G, Leroux A, Langlade-Demoyen P, Bahraoui M, Traincard F, Fisher R, Plata F. Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. J Immunol 1991; 147:2302-9.
30. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993; 581:33-55.
31. Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR, Zweerink HJ. Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J Immunol Methods 1991; 139:41-47.
32. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A, Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987; 326:881-2.
33. Widmann C, Maryanski JL, Romero P, Corradin G. Differential stability of antigenic MHC class 1 restricted synthetic peptides. J Immunol 1991; 147:3745-51.
34. Valmori D, Sabbatini A, Lanzavecchia A, Corradin G, Matricardi PA. Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR 1104 alleles. J Immunol 1994; 152:2921-9.
35. Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol 1994; 152:549-56.
36. Jacobson S, Shida H, McFarlin DE, Fauci A, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-1 px patients with HTLV-1 associated neurological disease. Nature 1990; 348:245-8.
37. Taswell C. A solution to the problems of cytolysis assays with additional applications to other immunological and biomedical assays. J Immunol 1987; 138:333-41.
38. Cerny A, McHutchison JG, Pasquinelle C et al. Cytotoxic T lymphocyte response to hepatitis C virus derived peptides containing the HLA-A2.1 binding motif. J Clin Invest 1995; 95:521-30.
39. Aichele P, Kyburz D, Ohashi PS, Odermatt B, Zinkernagel RM, Hengartner H, Pircher H. Peptide induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci USA 1994; 91:444-8.
40. Norman PS, Ohman JL, Long AA et al. Follow on study of the first clinical trial with T cell defined peptides from cat allergen Fel d. Allergy Clin Immunol 1995; 95:259.
41. Norman PS, Ohman JL, Long AA et al. Early clinical experience with T cell reactive peptides from cat allergen Fel d. Allergy Clin Immunol 1994; 94:231.